Skip to content

Recommendations for the Development of Rare Disease Drugs using the Accelerated Approval Pathway and for Qualifying Biomarkers as Primary Endpoints in Pivotal Clinical Studies

Share this page

Rare Disease challenges have been recognized by all stakeholders who endorse the need for flexibility in the regulatory review process for novel therapeutics to treat rare diseases. I

Related Articles